{"id":14634,"date":"2023-05-25T22:12:48","date_gmt":"2023-05-26T02:12:48","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/?post_type=private_project&#038;p=14634"},"modified":"2025-02-28T12:05:52","modified_gmt":"2025-02-28T17:05:52","slug":"chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario","status":"publish","type":"private_project","link":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\/","title":{"rendered":"Chronic lymphocytic-leukemia: associated incidence, prevalence, and treatment patterns in Ontario"},"content":{"rendered":"\n<p><strong>Client:<\/strong> IQVIA Solutions Canada Inc.<br><br><strong>Project ID:<\/strong> P2020-080 \/ 2022 0970 261 000<\/p>\n\n\n\n<p><strong>Research Question\/Objectives:<\/strong> CLL is a type of blood cancer that begins in the bone marrow and usually develops slowly over months or years. In 2016, an estimated 1,745 Canadians were diagnosed with CLL. With the emergence of various therapies for CLL, it is important to understand the real world impact of CLL on the patient and the healthcare system. The analysis will examine characteristics of patients in the \u201cwatch and wait\u201d status and patients that initiate 1st line (1L) treatment, by therapy type. This report will also help to validate\/compare US-based CLL patient characteristics to a Canadian population.<\/p>\n\n\n\n<p><strong>Objectives:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Identify CLL patients within the administrative data held at ICES.<\/li>\n\n\n\n<li>Describe the characteristics of these cancer patients in Ontario, including: incidence (i.e. new patients); prevalence (i.e. existing patients).<\/li>\n\n\n\n<li>Describe the characteristics of these cancer patients in Ontario, stratified by 1L therapy type as sample size allows, including: demographic characteristics, clinical characteristics, and; treatment patterns of attending physician visits and medication use.<\/li>\n<\/ul>\n\n\n\n<p><strong>Status<\/strong>: Completed<\/p>\n\n\n\n<p><strong>Results: <\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>December 2022<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Client: IQVIA Solutions Canada Inc. Project ID: P2020-080 \/ 2022 0970 261 000 Research Question\/Objectives: CLL is a type of blood cancer that begins in the bone marrow and usually develops slowly over months or years. In 2016, an estimated 1,745 Canadians were diagnosed with CLL. With the emergence of various therapies for CLL, it [&hellip;]<\/p>\n","protected":false},"template":"","organization_type":[],"project_status":[105],"response_type":[],"class_list":["post-14634","private_project","type-private_project","status-publish","hentry","project_status-completed"],"acf":{"project_id":"P2020-080 \/ 2022 0970 261 000","project_id_year":2021,"ices_scientist":"","principal_investigators":null,"knowledge_user":"","client":"","objectives":"","results":"","availability_of_results":"","pia_approved":null,"infographic":"","sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Chronic lymphocytic-leukemia: associated incidence, prevalence, and treatment patterns in Ontario | ICES<\/title>\n<meta name=\"description\" content=\"Client: IQVIA Solutions Canada Inc.Project ID: P2020-080 \/ 2022 0970 261 000 Research Question\/Objectives: CLL is a type of blood cancer that begins in\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chronic lymphocytic-leukemia: associated incidence, prevalence, and treatment patterns in Ontario | ICES\" \/>\n<meta property=\"og:description\" content=\"Client: IQVIA Solutions Canada Inc.Project ID: P2020-080 \/ 2022 0970 261 000 Research Question\/Objectives: CLL is a type of blood cancer that begins in\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-28T17:05:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\\\/\",\"name\":\"Chronic lymphocytic-leukemia: associated incidence, prevalence, and treatment patterns in Ontario | ICES\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2023-05-26T02:12:48+00:00\",\"dateModified\":\"2025-02-28T17:05:52+00:00\",\"description\":\"Client: IQVIA Solutions Canada Inc.Project ID: P2020-080 \\\/ 2022 0970 261 000 Research Question\\\/Objectives: CLL is a type of blood cancer that begins in\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Private Sector Projects\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Chronic lymphocytic-leukemia: associated incidence, prevalence, and treatment patterns in Ontario\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chronic lymphocytic-leukemia: associated incidence, prevalence, and treatment patterns in Ontario | ICES","description":"Client: IQVIA Solutions Canada Inc.Project ID: P2020-080 \/ 2022 0970 261 000 Research Question\/Objectives: CLL is a type of blood cancer that begins in","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\/","og_locale":"fr_FR","og_type":"article","og_title":"Chronic lymphocytic-leukemia: associated incidence, prevalence, and treatment patterns in Ontario | ICES","og_description":"Client: IQVIA Solutions Canada Inc.Project ID: P2020-080 \/ 2022 0970 261 000 Research Question\/Objectives: CLL is a type of blood cancer that begins in","og_url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2025-02-28T17:05:52+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\/","url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\/","name":"Chronic lymphocytic-leukemia: associated incidence, prevalence, and treatment patterns in Ontario | ICES","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2023-05-26T02:12:48+00:00","dateModified":"2025-02-28T17:05:52+00:00","description":"Client: IQVIA Solutions Canada Inc.Project ID: P2020-080 \/ 2022 0970 261 000 Research Question\/Objectives: CLL is a type of blood cancer that begins in","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/chronic-lymphocytic-leukemia-associated-incidence-prevalence-and-treatment-patterns-in-ontario\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Private Sector Projects","item":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/"},{"@type":"ListItem","position":3,"name":"Chronic lymphocytic-leukemia: associated incidence, prevalence, and treatment patterns in Ontario"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/private_project\/14634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/private_project"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/private_project"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=14634"}],"wp:term":[{"taxonomy":"organization_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/organization_type?post=14634"},{"taxonomy":"project_status","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/project_status?post=14634"},{"taxonomy":"response_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/response_type?post=14634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}